Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 36Pancreatic Neoplasms 26Rectal Neoplasms 15Esophageal Neoplasms 13Colonic Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 8Gastrointestinal Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma Of Esophagus 7Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Melanoma 3Liver Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Kidney Neoplasms 2Gastrointestinal Diseases 2Endometrial Neoplasms 2Carcinoma 2

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Fluorouracil × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡